TEVA PHARMACEUTICAL INDUSTRIES LIMITED Research and Development Expense
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Research and Development Expense of $98.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-02-10
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development expense for the quarter ending 2022-12-31 was $8.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development expense for the quarter ending 2022-09-30 was $17.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development expense for the quarter ending 2022-06-30 was $19.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development expense for the quarter ending 2022-03-31 was $54.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development expense for fiscal 2022 was $98.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development expense for fiscal 2018 was $114.00M, a 34.86% decline from fiscal 2017.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development expense for fiscal 2017 was $175.00M, a 58.53% decline from fiscal 2016.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED research and development expense for fiscal 2016 was $422.00M, a 1105.71% increase from fiscal 2015.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $25.00M derived: sum of 2 quarters · filed 2023-02-10 | $44.00M derived: sum of 3 quarters · filed 2023-02-10 | $98.00M 10-K · filed 2023-02-10 |
| 2022-09-30 | $17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $36.00M derived: sum of 2 quarters · filed 2022-11-03 | $90.00M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $73.00M 10-Q · filed 2022-07-27 | ||
| 2022-03-31 | $54.00M 10-Q · filed 2022-05-03 | |||
| 2018-12-31 | $60.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $60.00M derived: sum of 2 quarters · filed 2020-02-21 | $60.00M derived: sum of 3 quarters · filed 2020-02-21 | $114.00M 10-K · filed 2020-02-21 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $54.00M 10-Q · filed 2019-11-07 | $54.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $54.00M 10-Q · filed 2019-08-07 | $54.00M derived: sum of 3 quarters · filed 2020-02-21 | $229.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $54.00M 10-Q · filed 2019-05-02 | $54.00M derived: sum of 2 quarters · filed 2020-02-21 | $229.00M derived: sum of 3 quarters · filed 2020-02-21 | $229.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $175.00M derived: sum of 2 quarters · filed 2020-02-21 | $175.00M derived: sum of 3 quarters · filed 2020-02-21 | $175.00M 10-K · filed 2020-02-21 |
| 2017-09-30 | $175.00M derived: 10-Q 9 month − 6-K 6 month · filed 2018-11-01 | $175.00M derived: sum of 2 quarters · filed 2018-11-01 | $175.00M 10-Q · filed 2018-11-01 | $335.00M derived: sum of 4 quarters · filed 2018-11-01 |
| 2017-06-30 | $0.00 derived: 6-K 6 month − 6-K 3 month · filed 2017-08-03 | $0.00 6-K · filed 2017-08-03 | $160.00M derived: sum of 3 quarters · filed 2018-02-12 | $412.00M derived: sum of 4 quarters · filed 2018-02-12 |
| 2017-03-31 | $0.00 6-K · filed 2017-05-11 | $160.00M derived: sum of 2 quarters · filed 2018-02-12 | $412.00M derived: sum of 3 quarters · filed 2018-02-12 | $412.00M derived: sum of 4 quarters · filed 2018-02-12 |
| 2016-12-31 | $160.00M derived: 10-K 12 month − 6-K 9 month · filed 2018-02-12 | $412.00M derived: sum of 2 quarters · filed 2018-02-12 | $412.00M derived: sum of 3 quarters · filed 2018-02-12 | $422.00M 10-K · filed 2019-02-19 |
| 2016-09-30 | $252.00M derived: 6-K 9 month − 6-K 6 month · filed 2017-11-02 | $252.00M derived: sum of 2 quarters · filed 2017-11-02 | $262.00M 6-K · filed 2017-11-02 | $273.00M derived: sum of 4 quarters · filed 2018-02-12 |
| 2016-06-30 | $0.00 derived: 6-K 6 month − 6-K 3 month · filed 2017-08-03 | $10.00M 6-K · filed 2017-08-03 | $21.00M derived: sum of 3 quarters · filed 2018-02-12 | $21.00M derived: sum of 4 quarters · filed 2018-02-12 |
| 2016-03-31 | $10.00M 6-K · filed 2017-05-11 | $21.00M derived: sum of 2 quarters · filed 2018-02-12 | $21.00M derived: sum of 3 quarters · filed 2018-02-12 | $45.00M derived: sum of 4 quarters · filed 2018-02-12 |
| 2015-12-31 | $11.00M derived: 10-K 12 month − 6-K 9 month · filed 2018-02-12 | $11.00M derived: sum of 2 quarters · filed 2018-02-12 | $35.00M derived: sum of 3 quarters · filed 2018-02-12 | $35.00M 10-K · filed 2018-02-12 |
| 2015-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2016-11-15 | $24.00M derived: sum of 2 quarters · filed 2016-11-15 | $24.00M 6-K · filed 2016-11-15 | $24.00M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-06-30 | $24.00M derived: 6-K 6 month − 6-K 3 month · filed 2016-08-04 | $24.00M 6-K · filed 2016-08-04 | $24.00M derived: sum of 3 quarters · filed 2017-02-15 | $24.00M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-03-31 | $0.00 6-K · filed 2016-05-09 | $0.00 derived: sum of 2 quarters · filed 2017-02-15 | $0.00 derived: sum of 3 quarters · filed 2017-02-15 | |
| 2014-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2017-02-15 | $0.00 derived: sum of 2 quarters · filed 2017-02-15 | $0.00 20-F · filed 2017-02-15 | |
| 2014-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2015-10-29 | $0.00 6-K · filed 2015-10-29 | ||
| 2014-06-30 | $0.00 6-K · filed 2015-07-30 | |||
| 2013-12-31 | $5.00M 20-F · filed 2016-02-11 | |||
| 2012-12-31 | $73.00M 20-F · filed 2015-02-09 | |||
| 2011-12-31 | $15.00M 20-F · filed 2014-02-10 |